Literature DB >> 11819765

HCV-RNA positivity in peripheral blood mononuclear cells of patients with chronic HCV infection: does it really mean viral replication?

V Meier1, S Mihm, P Braun Wietzke, G Ramadori.   

Abstract

AIM: To analyze the association of HCV-RNA with peripheral blood mononuclear cells (PBMC) and to answer the question whether HCV-RNA positivity in PBMC is due to viral replication.
METHODS: HCV-RNA was monitored in serum and PBMC preparations from 15 patients with chronic HCV infection before, during and after an IFN-alpha therapy using a nested RT/PCR technique. In a second approach, PBMC from healthy donors were incubated in HCV positive plasma.
RESULTS: In the IFN-alpha responding patients,HCV-RNA disappeared first from total RNA preparations of PBMC and then from serum. In contrast, in relapsing patients, HCV-RNA reappeared first in serum and then in PBMC. A quantitative analysis of the HCV-RNA concentration in serum was performed before and after transition from detectable to non detectable HCV-RNA in PBMC-RNA and vice versa. When HCV-RNA was detectable in PBMC preparations, the HCV concentration in serum was significantly higher than the serum HCV-RNA concentration when HCV-RNA in PBMC was not detectable. Furthermore, at no time during the observation period was HCV specific RNA observed in PBMC, if HCV-RNA in serum was under the detection limit. Incubation of PBMC from healthy donors with several dilutions of HCV positive plasma for two hours showed a concentration dependent PCR positivity for HCV-RNA in reisolated PBMC.
CONCLUSION: The detectability of HCV-RNA in total RNA from PBMC seems to depend on the HCV concentration in serum. Contamination or passive adsorption by circulating virus could be the reason for detection of HCV-RNA in PBMC preparations of chronically infected patients.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11819765      PMCID: PMC4723527          DOI: 10.3748/wjg.v7.i2.228

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  37 in total

1.  Fluorescent "in situ" hybridization of hepatitis C virus RNA in peripheral blood mononuclear cells from patients with chronic hepatitis C.

Authors:  E Rodríguez-Iñigo; M Casqueiro; S Navas; J Bartolomé; M Pardo; V Carreño
Journal:  J Med Virol       Date:  2000-03       Impact factor: 2.327

2.  Density heterogeneities of hepatitis C virus in human sera due to the binding of beta-lipoproteins and immunoglobulins.

Authors:  R Thomssen; S Bonk; A Thiele
Journal:  Med Microbiol Immunol       Date:  1993-12       Impact factor: 3.402

3.  Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis.

Authors:  H J Alter; R H Purcell; J W Shih; J C Melpolder; M Houghton; Q L Choo; G Kuo
Journal:  N Engl J Med       Date:  1989-11-30       Impact factor: 91.245

4.  Inhibition of hepatitis C virus adsorption to peripheral blood mononuclear cells by dextran sulfate.

Authors:  B Cribier; C Schmitt; A Kirn; F Stoll-Keller
Journal:  Arch Virol       Date:  1998       Impact factor: 2.574

5.  Hepatitis C virus reinfection in allografts after orthotopic liver transplantation.

Authors:  V König; J Bauditz; H Lobeck; R Lüsebrink; P Neuhaus; G Blumhardt; W O Bechstein; R Neuhaus; R Steffen; U Hopf
Journal:  Hepatology       Date:  1992-11       Impact factor: 17.425

6.  Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT)

Authors:  T Poynard; P Marcellin; S S Lee; C Niederau; G S Minuk; G Ideo; V Bain; J Heathcote; S Zeuzem; C Trepo; J Albrecht
Journal:  Lancet       Date:  1998-10-31       Impact factor: 79.321

Review 7.  Treatment of hepatocellular carcinoma associated with cirrhosis in the era of liver transplantation.

Authors:  E Mor; R Tur-Kaspa; P Sheiner; M Schwartz
Journal:  Ann Intern Med       Date:  1998-10-15       Impact factor: 25.391

8.  Detection of hepatitis C virus (HCV) proteins by immunofluorescence and HCV RNA genomic sequences by non-isotopic in situ hybridization in bone marrow and peripheral blood mononuclear cells of chronically HCV-infected patients.

Authors:  D Sansonno; A R Iacobelli; V Cornacchiulo; G Iodice; F Dammacco
Journal:  Clin Exp Immunol       Date:  1996-03       Impact factor: 4.330

9.  Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group.

Authors:  J G McHutchison; S C Gordon; E R Schiff; M L Shiffman; W M Lee; V K Rustgi; Z D Goodman; M H Ling; S Cort; J K Albrecht
Journal:  N Engl J Med       Date:  1998-11-19       Impact factor: 91.245

10.  Effect of interferon therapy on hepatitis C virus RNA in whole blood, plasma, and peripheral blood mononuclear cells.

Authors:  W N Schmidt; P Wu; D Brashear; D Klinzman; M J Phillips; D R LaBrecque; J T Stapleton
Journal:  Hepatology       Date:  1998-10       Impact factor: 17.425

View more
  12 in total

1.  Identification of the epitopes on HCV core protein recognized by HLA-A2 restricted cytotoxic T lymphocytes.

Authors:  H C Zhou; D Z Xu; X P Wang; J X Zhang; Y Huang; Y P Yan; Y Zhu; B Q Jin
Journal:  World J Gastroenterol       Date:  2001-08       Impact factor: 5.742

2.  A small yeast RNA inhibits HCV IRES mediated translation and inhibits replication of poliovirus in vivo.

Authors:  Xue-Song Liang; Jian-Qi Lian; Yong-Xing Zhou; Qing-He Nie; Chun-Qiu Hao
Journal:  World J Gastroenterol       Date:  2003-05       Impact factor: 5.742

Review 3.  RNA interference: antiviral weapon and beyond.

Authors:  Quan-Chu Wang; Qing-He Nie; Zhi-Hua Feng
Journal:  World J Gastroenterol       Date:  2003-08       Impact factor: 5.742

4.  Management of Hepatitis C in HIV-infected Patients.

Authors:  Benigno Rodriguez; David A Bobak
Journal:  Curr Infect Dis Rep       Date:  2005-03       Impact factor: 3.725

5.  Preparation of human single chain Fv antibody against hepatitis C virus E2 protein and its identification in immunohistochemistry.

Authors:  Yan-Wei Zhong; Jun Cheng; Gang Wang; Shuang-Shuang Shi; Li Li; Ling-Xia Zhang; Ju-Mei Chen
Journal:  World J Gastroenterol       Date:  2002-10       Impact factor: 5.742

6.  HCV replication in PBMC and its influence on interferon therapy.

Authors:  Guo-Zhong Gong; Li-Ying Lai; Yong-Fang Jiang; Yan He; Xian-Shi Su
Journal:  World J Gastroenterol       Date:  2003-02       Impact factor: 5.742

7.  Genetic evolution of structural region of hepatitis C virus in primary infection.

Authors:  Song Chen; Yu-Ming Wang
Journal:  World J Gastroenterol       Date:  2002-08       Impact factor: 5.742

8.  The blood transcriptional signature of chronic hepatitis C virus is consistent with an ongoing interferon-mediated antiviral response.

Authors:  Christopher R Bolen; Michael D Robek; Leonid Brodsky; Vincent Schulz; Joseph K Lim; Milton W Taylor; Steven H Kleinstein
Journal:  J Interferon Cytokine Res       Date:  2012-10-15       Impact factor: 2.607

9.  Hepatitis C virus RNA quantitation in venous and capillary small-volume whole-blood samples.

Authors:  Tony Bruns; Katrin Steinmetzer; Eugen Ermantraut; Andreas Stallmach
Journal:  J Clin Microbiol       Date:  2009-08-19       Impact factor: 5.948

10.  Sequence evolution of putative cytotoxic T cell epitopes in NS3 region of hepatitis C virus.

Authors:  Hua-Zhang Guo; Ying Yin; Wen-Liang Wang; Chuan-Shan Zhang; Tao Wang; Zhe Wang; Jing Zhang; Hong Cheng; Hai-Tao Wang
Journal:  World J Gastroenterol       Date:  2004-03-15       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.